Clinical Trial Update: An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial studying telaprevir for genotype 1 hepatitis C infection in liver transplant recipients has completed, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Chronic Hepatitis C Virus (HCV) Infection | Phase 3 | Status: COMPLETED